BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Bio NC

  3 Small-Cap Biotechs With the Most Promising New Antibiotics in Clinical Trials

  New antibiotic development seems to go through cycles and many large companies have stayed away from antibiotics or abandoned efforts, despite a growing need for new antibiotics.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Touts Late-Stage Psoriasis Drug Trial Data

  AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J’s Stelara for psoriasis patients.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Beach

  Impact Biomedicines’ High-Risk Gamble on Failed Sanofi Drug Gains $90M Financing

  Impact Biomedicines closed on a $90M structured financing with Oberland Capital.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Neos Therapeutics Jumps After PDL BioPharma Makes an All-Cash Take Out Offer

  Shares of Neos Therapeutics have soared more than 38 percent this morning after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287M.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• Drug Development

  Neurana Pharma Reports Successful Results in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

  Neurana Pharma today announced the successful top-line results from a clinical trial designed to confirm the non-sedative effects of tolperisone.

  October 26, 2017

   · 

  4 min read
• Policy

  FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women With Advanced Ovarian Cancer

  Genentech announced today that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer.

  October 26, 2017

   · 

  10 min read
• Business

  Ipsen Delivers Strong Sales Growth of 22.6% for the Third Quarter of 2017 and Confirms Full Year Guidance

  Ipsen, a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017.

  October 26, 2017

   · 

  29 min read
• Business

  Epidarex Capital Appoints Three Leading Industry Executives to its Advisory Board

  Epidarex Capital, an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William Burns and Dr. Frank M Armstrong to its advisory board.

  October 26, 2017

   · 

  6 min read
• Drug Development

  New Data Suggest Slowing of Cortical Gray Matter Atrophy with Sanofi Genzyme’s Aubagio (teriflunomide) is Associated with Delayed Conversion to Clinically Definite Multiple Sclerosis

  Sanofi Genzyme announced today new investigational data that suggest slowing of cortical gray matter volume loss (atrophy) with Aubagio (teriflunomide) is associated with delayed conversion to clinically definite multiple sclerosis.

  October 26, 2017

   · 

  9 min read
• Business

  PierianDx Names New Additions to Sales and Clinical Genomic Solutions Teams

  PierianDx announced today two key additions that will expand the organization’s reach into health systems and global markets while deepening clinical expertise.

  October 26, 2017

   · 

  3 min read